The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

For some patients born with a certain skull abnormality, unexpectedly early cognitive decline and symptoms of depression and anxiety may be corrected with a brain surgery, report University of ...

Johns Hopkins University School of Medicine researchers have discovered a dual regulatory mechanism safeguarding ...

NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting ...

A two-and-a-half-year-old girl shows no signs of a rare genetic disorder, after becoming the first person to be treated for ...

Researchers at Jilin University (Changchun, China) developed a highly sensitive, rapid, and accurate method for analyzing ...